Cargando…
Pneumonia hospitalizations of children aged <2 years in Poland before (2013–2016) and after (2017–2018) universal mass vaccination with 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine
As infection with Streptococcus pneumoniae is an important cause of pneumonia in children, the World Health Organization recommends childhood pneumococcal conjugate vaccines (PCVs). In January 2017, PCV universal mass vaccination (UMV) was introduced in Poland for children aged <2 years. The obje...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Taylor & Francis
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9746359/ https://www.ncbi.nlm.nih.gov/pubmed/36239615 http://dx.doi.org/10.1080/21645515.2022.2128566 |
_version_ | 1784849339710963712 |
---|---|
author | Bhavsar, Amit Zaryczański, Janusz Wasilewska, Anna Saragoussi, Delphine Devadiga, Raghavendra Colby, Chris Bahar, Enas Wysocki, Jacek |
author_facet | Bhavsar, Amit Zaryczański, Janusz Wasilewska, Anna Saragoussi, Delphine Devadiga, Raghavendra Colby, Chris Bahar, Enas Wysocki, Jacek |
author_sort | Bhavsar, Amit |
collection | PubMed |
description | As infection with Streptococcus pneumoniae is an important cause of pneumonia in children, the World Health Organization recommends childhood pneumococcal conjugate vaccines (PCVs). In January 2017, PCV universal mass vaccination (UMV) was introduced in Poland for children aged <2 years. The objective of this study was to estimate and describe the trends in the incidences of various types of pneumonia hospitalizations in Poland before (2013–2016) and after (2017–2018) introduction of the UMV program. The study was conducted at the regional hospitals of Opole and Bialystok and included all hospitalized children aged <2 years with a primary or secondary diagnosis of pneumonia in their electronic medical records. Pneumonia diagnoses were identified based on International Classification of Diseases 10(th) revision (ICD-10) codes for bacterial, viral, and other/unknown-cause pneumonias. The effect of the implementation of PCV UMV was modeled via an inferential multivariate model. Among 4,168 children included in the study, 64.3% were admitted before PCV UMV. The number of radiograph-confirmed likely bacterial pneumonia cases varied between 55 and 176 cases per 100,000 person-years, and no trend was observed over time. However, inferential modeling showed statistically significant decreasing trends in the incidence rates of bacterial-coded pneumonia (28.48%), viral-coded pneumonia (35.36%), all-cause pneumonia (24.60%), and radiograph-confirmed likely non-bacterial pneumonia (24.98%) among children eligible for UMV. This might be the first indication of the impact of the PCV UMV program in Poland. |
format | Online Article Text |
id | pubmed-9746359 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Taylor & Francis |
record_format | MEDLINE/PubMed |
spelling | pubmed-97463592022-12-14 Pneumonia hospitalizations of children aged <2 years in Poland before (2013–2016) and after (2017–2018) universal mass vaccination with 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine Bhavsar, Amit Zaryczański, Janusz Wasilewska, Anna Saragoussi, Delphine Devadiga, Raghavendra Colby, Chris Bahar, Enas Wysocki, Jacek Hum Vaccin Immunother Pneumococcal – Research Article As infection with Streptococcus pneumoniae is an important cause of pneumonia in children, the World Health Organization recommends childhood pneumococcal conjugate vaccines (PCVs). In January 2017, PCV universal mass vaccination (UMV) was introduced in Poland for children aged <2 years. The objective of this study was to estimate and describe the trends in the incidences of various types of pneumonia hospitalizations in Poland before (2013–2016) and after (2017–2018) introduction of the UMV program. The study was conducted at the regional hospitals of Opole and Bialystok and included all hospitalized children aged <2 years with a primary or secondary diagnosis of pneumonia in their electronic medical records. Pneumonia diagnoses were identified based on International Classification of Diseases 10(th) revision (ICD-10) codes for bacterial, viral, and other/unknown-cause pneumonias. The effect of the implementation of PCV UMV was modeled via an inferential multivariate model. Among 4,168 children included in the study, 64.3% were admitted before PCV UMV. The number of radiograph-confirmed likely bacterial pneumonia cases varied between 55 and 176 cases per 100,000 person-years, and no trend was observed over time. However, inferential modeling showed statistically significant decreasing trends in the incidence rates of bacterial-coded pneumonia (28.48%), viral-coded pneumonia (35.36%), all-cause pneumonia (24.60%), and radiograph-confirmed likely non-bacterial pneumonia (24.98%) among children eligible for UMV. This might be the first indication of the impact of the PCV UMV program in Poland. Taylor & Francis 2022-10-14 /pmc/articles/PMC9746359/ /pubmed/36239615 http://dx.doi.org/10.1080/21645515.2022.2128566 Text en © 2022 GSK. Published with license by Taylor & Francis Group, LLC. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives License (http://creativecommons.org/licenses/by-nc-nd/4.0/ (https://creativecommons.org/licenses/by-nc-nd/4.0/) ), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited, and is not altered, transformed, or built upon in any way. |
spellingShingle | Pneumococcal – Research Article Bhavsar, Amit Zaryczański, Janusz Wasilewska, Anna Saragoussi, Delphine Devadiga, Raghavendra Colby, Chris Bahar, Enas Wysocki, Jacek Pneumonia hospitalizations of children aged <2 years in Poland before (2013–2016) and after (2017–2018) universal mass vaccination with 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine |
title | Pneumonia hospitalizations of children aged <2 years in Poland before (2013–2016) and after (2017–2018) universal mass vaccination with 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine |
title_full | Pneumonia hospitalizations of children aged <2 years in Poland before (2013–2016) and after (2017–2018) universal mass vaccination with 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine |
title_fullStr | Pneumonia hospitalizations of children aged <2 years in Poland before (2013–2016) and after (2017–2018) universal mass vaccination with 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine |
title_full_unstemmed | Pneumonia hospitalizations of children aged <2 years in Poland before (2013–2016) and after (2017–2018) universal mass vaccination with 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine |
title_short | Pneumonia hospitalizations of children aged <2 years in Poland before (2013–2016) and after (2017–2018) universal mass vaccination with 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine |
title_sort | pneumonia hospitalizations of children aged <2 years in poland before (2013–2016) and after (2017–2018) universal mass vaccination with 10-valent pneumococcal non-typeable haemophilus influenzae protein d conjugate vaccine |
topic | Pneumococcal – Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9746359/ https://www.ncbi.nlm.nih.gov/pubmed/36239615 http://dx.doi.org/10.1080/21645515.2022.2128566 |
work_keys_str_mv | AT bhavsaramit pneumoniahospitalizationsofchildrenaged2yearsinpolandbefore20132016andafter20172018universalmassvaccinationwith10valentpneumococcalnontypeablehaemophilusinfluenzaeproteindconjugatevaccine AT zaryczanskijanusz pneumoniahospitalizationsofchildrenaged2yearsinpolandbefore20132016andafter20172018universalmassvaccinationwith10valentpneumococcalnontypeablehaemophilusinfluenzaeproteindconjugatevaccine AT wasilewskaanna pneumoniahospitalizationsofchildrenaged2yearsinpolandbefore20132016andafter20172018universalmassvaccinationwith10valentpneumococcalnontypeablehaemophilusinfluenzaeproteindconjugatevaccine AT saragoussidelphine pneumoniahospitalizationsofchildrenaged2yearsinpolandbefore20132016andafter20172018universalmassvaccinationwith10valentpneumococcalnontypeablehaemophilusinfluenzaeproteindconjugatevaccine AT devadigaraghavendra pneumoniahospitalizationsofchildrenaged2yearsinpolandbefore20132016andafter20172018universalmassvaccinationwith10valentpneumococcalnontypeablehaemophilusinfluenzaeproteindconjugatevaccine AT colbychris pneumoniahospitalizationsofchildrenaged2yearsinpolandbefore20132016andafter20172018universalmassvaccinationwith10valentpneumococcalnontypeablehaemophilusinfluenzaeproteindconjugatevaccine AT baharenas pneumoniahospitalizationsofchildrenaged2yearsinpolandbefore20132016andafter20172018universalmassvaccinationwith10valentpneumococcalnontypeablehaemophilusinfluenzaeproteindconjugatevaccine AT wysockijacek pneumoniahospitalizationsofchildrenaged2yearsinpolandbefore20132016andafter20172018universalmassvaccinationwith10valentpneumococcalnontypeablehaemophilusinfluenzaeproteindconjugatevaccine |